hide
Free keywords:
GLUCAGON-LIKE PEPTIDE-1; LOW ABUNDANCE PROTEINS; OBESE-PATIENTS; CELLS;
SECRETION; INTESTINE; HORMONE; GLP-1; PHARMACOKINETICS; QUANTIFICATIONGeneral & Internal Medicine; Gut hormones; GLP-1; Low-abundant peptides; Mass-spectrometry;
Proteomics;
Abstract:
Low-abundance regulatory peptides, including metabolically important gut hormones, have shown promising therapeutic potential. Here, we present a streamlined mass spectrometry-based platform for identifying and characterizing low-abundance regulatory peptides in humans. We demonstrate the clinical applicability of this platform by studying a hitherto neglected glucose-and appetite-regulating gut hormone, namely, oxyntomodulin. Our results show that the secretion of oxyntomodulin in patients with type 2 diabetes is significantly impaired, and that its level is increased by more than 10-fold after gastric bypass surgery. Furthermore, we report that oxyntomodulin is co-distributed and co-secreted with the insulin-stimulating and appetite-regulating gut hormone glucagon-like peptide-1 (GLP-1), is inactivated by the same protease (dipeptidyl peptidase-4) as GLP-1 and acts through its receptor. Thus, oxyntomodulin may participate with GLP-1 in the regulation of glucose metabolism and appetite in humans. In conclusion, this mass spectrometry-based platformis a powerful resource for identifying and characterizing metabolically active low-abundance peptides. (C) 2016 The Authors. Published by Elsevier B.V.
